RISK FACTORS AND INCIDENCE OF MYOCARDIAL DAMAGE IN PATIENTS WITH HEMOBLASTOSIS RECEIVING ANTHRACYCLIN ANTIBIOTICS

QR-Code

RISK FACTORS AND INCIDENCE OF MYOCARDIAL DAMAGE IN PATIENTS WITH HEMOBLASTOSIS RECEIVING ANTHRACYCLIN ANTIBIOTICS

Introduction. The anthracycline antibiotics cause clinically significant manifestations of cardiotoxicity (СТ) – myocardial injuries, reducing both quality and life expectancy of the oncological patients.The purpose of the study was to evaluate the incidence and risk factors anthracycline-induced СТ...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Hauptverfasser:	N. T. Vatutin, E. V. Sklyannaya, M. A. El-Khatib, I. A. Sologub
Format:	Artikel
Sprache:	Russisch
Veröffentlicht:	ABV-press 2017-10-01
Schriftenreihe:	Онкогематология
Schlagworte:	chemotherapy cardiotoxicity anthracycline-induced cardiomyopathy risk factors cardioprotection
Online-Zugang:	https://oncohematology.abvpress.ru/ongm/article/view/255
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge

The cardiovascular system in patients with anthracycline cardiomiopathy
von: Alexandr T. Teplyakov, et al.
Veröffentlicht: (2017-10-01)

Ischemic stroke as the first manifestation of anthracycline cardiomyopathy
von: G. R. Ramazanov, et al.
Veröffentlicht: (2023-01-01)

The prognostic value of the NT-proBNP biomarkers and Fas ligand in assessing the risk of cardiotoxicity of anthracycline chemotherapy
von: A. T. Teplyakov, et al.
Veröffentlicht: (2019-03-01)

Therapeutic Potential of Ginsenosides in Anthracycline-Induced Cardiotoxicity
von: Rongrong Bai, et al.
Veröffentlicht: (2025-06-01)

Lifestyle and Pharmacological Interventions to Prevent Anthracycline-Related Cardiotoxicity in Cancer Patients
von: Luigi Spadafora, et al.
Veröffentlicht: (2025-06-01)

MODERN VIEW ON CARDIOTOXICITY OF CHEMOTHERAPEUTICS IN ONCOLOGY INCLUDING ANTHRACYCLINES
von: G. E. Gendlin, et al.
Veröffentlicht: (2017-03-01)

Clinical and cost-effectiveness of pharmacogenomic testing for anthracycline-induced cardiotoxicity in childhood cancer: a systematic review and meta-analysis
von: Ling Yin Fritz Wong, et al.
Veröffentlicht: (2025-07-01)

Roles of Non-Coding RNA in Anthracycline Cardiotoxicity: A Narrative Review
von: Xiao S, et al.
Veröffentlicht: (2025-07-01)

POSSIBILITY OF DRUG PREVENTION ANTHRACYCLINE-INDUCED CARDIOTOXICITY
von: V. I. Chernov, et al.
Veröffentlicht: (2016-02-01)

Genetic basis of anthracyclines cardiotoxicity: Literature review
von: M. Yu. Sinitsky, et al.
Veröffentlicht: (2021-10-01)

Cardiovascular system state changes in non-Hodgkin’s lymphoma patients during chemotherapy
von: A.-S. O. Bady, et al.
Veröffentlicht: (2020-05-01)

POSSIBILITIES OF IVABRADINE, A SELECTIVE INHIBITOR OF ION F-CHANNELS OF SINUS NODE, IN PREVENTION OF ANTHRACYCLINE CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER
von: Yu. V. Vasyuk, et al.
Veröffentlicht: (2017-05-01)

Pharmacogenetics in treatment of anthracycline-induced cardiotoxicity in women without prior cardiovascular diseases
von: E. V. Grakova, et al.
Veröffentlicht: (2023-01-01)

CHANGE OF THE LEFT VENTRICLE FUNCTIONING IN LYMPHOMA TREATED WITH ANTHRACYCLINE ANTIBIOTICS
von: K. V. Shuykova, et al.
Veröffentlicht: (2016-01-01)

Interaction of Body Mass Index and Glycemic Status on Cardiovascular Outcomes in Patients With Cancer Treated With Anthracyclines
von: Iokfai Cheang, et al.
Veröffentlicht: (2025-06-01)

The role of doxorubicin in the formation of cardiotoxicity is a consensus statement. Part II. Cardiotoxicity of doxorubicin unrelated to myocytes and cardioprotection strategy (review)
von: D. A. Andreev, et al.
Veröffentlicht: (2024-09-01)

The Role of Doxorubicin in the Formation of Cardiotoxicity – Generally Accepted Statement. Part I. Prevalence and Mechanisms of Formation (Review)
von: D. A. Andreev, et al.
Veröffentlicht: (2024-03-01)

Relationship between Chemotherapy and Atrial Fibrillation: Clinical Case
von: A. A. Avagimyan, et al.
Veröffentlicht: (2021-11-01)

Potential New Applications of Sodium–Glucose Cotransporter-2 Inhibitors Across the Continuum of Cancer-Related Cardiovascular Toxicity
von: Agnieszka Maria Zebrowska, et al.
Veröffentlicht: (2025-06-01)

RADIONUCLIDE METHODS IN THE DETECTION AND FORECAST OF ANTHRACYCLINE-INDUCED CARDIOTOXICITY IN BREAST CANCER PATIENTS
von: V. I. Chernov, et al.
Veröffentlicht: (2016-12-01)

High-sensitivity troponin I as a predictor of left ventricular dysfunction in the use of cardiotoxic anticancer agents for breast cancer in patients with predominantly low and moderate risk of cardiotoxicity
von: V. D. Levina, et al.
Veröffentlicht: (2022-12-01)

Changes in left ventricular systolic and diastolic function after chemotherapy for breast cancer with doxorubicin
von: I. A. Karput, et al.
Veröffentlicht: (2024-01-01)

Course of arterial hypertension during breast cancer chemotherapy with anthracyclines
von: E. N. Berezikova, et al.
Veröffentlicht: (2024-10-01)

Mechanistic Insights into Flavonoid Subclasses as Cardioprotective Agents Against Doxorubicin-Induced Cardiotoxicity: A Comprehensive Review
von: Shang W, et al.
Veröffentlicht: (2025-07-01)

Ejection Fraction Decline and Cardiotoxicity Following Anthracycline Chemotherapy: A Risk-Focused Study from an Indonesian Tertiary Care Center
von: Rizkyastari Onny, et al.
Veröffentlicht: (2025-06-01)

Predictive and Prognostic Relevance of ABC Transporters for Resistance to Anthracycline Derivatives
von: Rümeysa Yücer, et al.
Veröffentlicht: (2025-07-01)

Omitting anthracyclines for the adjuvant treatment of patients with triple-negative breast cancer: A non-inferiority meta-analysis
von: Fabio Girardi, et al.
Veröffentlicht: (2025-10-01)

Cardioprotective effect of thiotriazoline in cancer patients
von: A. V. Koltsov, et al.
Veröffentlicht: (2023-02-01)

Longitudinal Assessment of QT Apex in Tumor‐Bearing Dogs Receiving Doxorubicin Monotherapy
von: Keita Kitagawa, et al.
Veröffentlicht: (2025-07-01)

Nuclear imaging of chemotherapy-induced cardiotoxicity
von: A. A. Ansheles, et al.
Veröffentlicht: (2021-03-01)

Cardiotoxicity of anticancer drugs and radiotherapy in patients with hematologic malignancies and solid tumors
von: L. M. Kogoniya, et al.
Veröffentlicht: (2022-07-01)

Creation of anthracycline prodrug
von: A. N. Tevyashova
Veröffentlicht: (2014-12-01)

CARDIOPROTECTIVE EFFECT OF TUMOR NECROSIS FACTOR ALPHA ANTAGONIST IN DOXORUBICIN MYOCARD TOXICITY
von: M. I. Popovich, et al.
Veröffentlicht: (2018-02-01)

Nosological features of myocardial injury: an overview of the symposium
von: E. O. Girutskaya
Veröffentlicht: (2021-07-01)

CHEMOTHERAPY CARDIOTOXICITY SCREENING WITH CARDIAC TROPONINS
von: O. V. Krikunova, et al.
Veröffentlicht: (2015-12-01)

Prognostic value of humoral markers in patients with anthracycline-related cardiac dysfunction
von: E. V. Grakova, et al.
Veröffentlicht: (2023-10-01)

Natural strategies of preventing anthracycline-induced cardiotoxicity – a review
von: Anca STOICA, et al.
Veröffentlicht: (2022-12-01)

Myocardial contractility dysfunction in patients with chronic lymphocytic leukemia receiving chemotherapy and their treatment with enalapril
von: I. L. Davydkin, et al.
Veröffentlicht: (2020-03-01)

Potential of primary drug prevention of cardiotoxicity in the context of anticancer therapy
von: Yu. A. Vasyuk, et al.
Veröffentlicht: (2023-01-01)

DIAGNOSIS AND PREVENTION OF CARDIOTOXICITY IN PATIENTS WITH BREAST CANCER FROM THE STANDPOINT OF AN ONCOLOGIST AND A CARDIOLOGIST
von: T. Yu. Semiglazova, et al.
Veröffentlicht: (2017-09-01)